We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03314207
Recruitment Status : Completed
First Posted : October 19, 2017
Last Update Posted : January 11, 2023
Information provided by (Responsible Party):
Applied Genetic Technologies Corp

Brief Summary:
The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.

Condition or disease
X-Linked Retinitis Pigmentosa

Detailed Description:
Males with a clinical diagnosis of X-linked retinitis pigmentosa (XLRP) caused by RPGR-ORF15 mutations will be asked to provide informed consent and will have a single blood or saliva sample obtained for DNA sequence analysis of genes known to cause XLRP, including the RPGR-ORF15 gene. All participants will be informed of the results of testing for these mutations. Those with qualifying mutations in the RPGR-ORF15 gene will be evaluated every 6 months for 3 years using a variety of non-invasive visual function tests to more fully characterize their clinical condition. Testing will include routine ophthalmic examinations and tests of visual acuity, perimetry, OCT, fundus imaging, and completion of quality of life questionnaires.

Layout table for study information
Study Type : Observational
Actual Enrollment : 14 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Evaluation of Individuals With X-linked Retinitis Pigmentosa (XLRP) Caused by RPGR-ORF15 Mutations
Actual Study Start Date : December 1, 2017
Actual Primary Completion Date : February 10, 2022
Actual Study Completion Date : February 10, 2022

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Disease progression in subjects with XLRP [ Time Frame: Day 0 - Month 36 ]

Secondary Outcome Measures :
  1. Disease progression using visual acuity testing [ Time Frame: Day 0 - Month 36 ]
  2. Disease progression using perimetry [ Time Frame: Day 0 - Month 36 ]
  3. Disease progression using OCT [ Time Frame: Day 0 - Month 36 ]
  4. Disease progression using electroretinography [ Time Frame: Day 0 - Month 36 ]
  5. Disease progression using the National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25) quality of life questionnaire [ Time Frame: Day 0 - Month 36 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Males with a clinical diagnosis of X-linked Retinitis Pigmentosa (XLRP)

Inclusion Criteria:

  • Male subjects with a clinical diagnosis of XLRP and a documented molecular diagnosis from a CLIA-certified laboratory of mutation within the ORF15 exon of the RPGR gene;
  • At least 6 years of age;
  • Willing and able to perform study procedures;
  • Signed informed consent(s) obtained (and child assent where applicable).

Exclusion Criteria:

  • Pre-existing eye conditions that would interfere with interpretation of study endpoints (e.g. glaucoma, corneal or lenticular opacities, diabetic retinopathy, history of retinal detachment);
  • Participating in an interventional research study of drugs or devices for treatment of XLRP or other retinal diseases;
  • Monoocular participants
  • Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03314207

Layout table for location information
United States, North Carolina
Duke Eye Center, Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Oregon
Casey Eye Institute, Oregon Health and Sciences University
Portland, Oregon, United States, 97239
United States, Texas
Retina Foundation of the Southwest
Dallas, Texas, United States, 75231
Sponsors and Collaborators
Applied Genetic Technologies Corp
Layout table for investigator information
Study Director: Matthew Feinsod, MD Applied Genetics Technologies Corporation
Layout table for additonal information
Responsible Party: Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier: NCT03314207    
Other Study ID Numbers: AGTC-XLRP-001
First Posted: October 19, 2017    Key Record Dates
Last Update Posted: January 11, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Applied Genetic Technologies Corp:
retinal degeneration
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinitis Pigmentosa
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn